• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

24.44 -1.05 (-4.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release ↗
May 01, 2026
Pacira BioSciences, a leader in non-opioid pain management, reported a notable insider sale amid ongoing option exercise activity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pacira (PCRX) Q1 2026 Earnings Call Transcript ↗
April 30, 2026
Pacira (PCRX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
Pacira Biosciences (NASDAQ:PCRX) Q1 2026 Results Beat Estimates as Key Pipeline Catalysts Near ↗
April 30, 2026
Via Chartmill
News headline image
Pacira BioSciences Reports First Quarter 2026 Financial Results
April 30, 2026
From Pacira BioSciences
Via GlobeNewswire
PACIRA BIOSCIENCES INC (NASDAQ:PCRX) Presents a Compelling Value Investment Case ↗
March 05, 2026
Via Chartmill
Pacira BioSciences Inc (NASDAQ:PCRX) Misses Q4 Earnings and Revenue Estimates, Shares Drop ↗
February 26, 2026
Via Chartmill
News headline image
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders
April 28, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
April 27, 2026
-- Findings show significant reductions in opioid consumption, healthcare resource utilization, and total medical costs -- 
From Pacira BioSciences
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
April 16, 2026
Via Chartmill
News headline image
Pacira to Report First Quarter 2026 Financial Results on Thursday April 30, 2026
April 16, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Organogenesis Clears Major FDA Hurdle: Path to First Non-Surgical Biologic for Knee Osteoarthritis Widens
April 13, 2026
CANTON, Mass. — In a milestone development for the regenerative medicine sector, Organogenesis Holdings Inc. (Nasdaq: ORGO) announced today that it has successfully concluded a pivotal Type B meeting... 
Via MarketMinute
News headline image
Pacira Presents Real-World Data on EXPAREL® Showing Lower Total Healthcare Costs in Outpatient Total Hip and Knee Arthroplasty Procedures
April 13, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Present Real-World Data on EXPAREL® Showing Reduced Cost of Care at Orthopaedic Research Society 2026 Annual Meeting
March 30, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reaffirms Commitment to Shareholder Value Creation
March 11, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at the Barclays 28th Annual Global Healthcare Conference
March 04, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Presents Two Real-World Studies from Its Innovations in Genicular Outcomes Registry (IGOR)
March 02, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira (PCRX) Q4 2025 Earnings Call Transcript ↗
February 26, 2026
Pacira (PCRX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
February 26, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
February 12, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
February 12, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 09, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
January 28, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
January 13, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
January 08, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
January 07, 2026
From Pacira BioSciences
Via GlobeNewswire
News headline image
Bridge City Capital Loads Up Onto Innovation Stock With Over 31,000 Shares ↗
December 22, 2025
Post-trade holding: 47,342 shares valued at approximately $6.12 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care
December 18, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain
December 02, 2025
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap